The 21-gene recurrence score (RS) assay (Oncotype DX®; Genomic Health, Inc., Redwood City, CA) available since 2004 is one of the promising tools to guide treatment decisions in hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients [2, 3]. Here, NR4A1 is linked to breast carcinoma.